NeuroOne Advances StereoCED Brain Drug Delivery Platform With Successful Robotic Procedures

Key Points

• NeuroOne completed three robotic-assisted large-animal StereoCED procedures.
• Two procedures combined targeted drug delivery with intracranial electrophysiological recording from the same brain region.
• The work was completed at the University of Minnesota as part of an epilepsy research program.
• Animal-use StereoCED devices are expected to generate revenue during fiscal Q4 2026.
• Human investigational-use devices are expected to be available by the end of fiscal Q4 2026.
• StereoCED is not yet approved or cleared for commercial human use.

 NeuroOne Medical Technologies (NASDAQ: NMTC) reported successful robotic-assisted large-animal procedures using its next-generation StereoCED platform, moving the company closer to planned human investigational studies later in fiscal Q4 2026. The platform is designed to deliver therapeutic agents precisely into targeted brain tissue while also recording electrical activity from the same location.

Robotic StereoCED Procedures Validate Targeted Brain Drug Delivery Workflow

NeuroOne completed three large-animal procedures using a robotic surgical workflow to plan the treatment path, create the access point, place an anchor bolt, and guide the StereoCED electrode and catheter into targeted brain tissue. The system then delivered an investigational agent directly to the selected region.

The successful procedures provide early technical validation that the platform can be deployed consistently using robotic guidance. This is an important development step before the company begins planned human investigational clinical studies.

Drug Delivery and Brain-Signal Recording Could Support More Precise Epilepsy Research

In two of the procedures, StereoCED both delivered a study agent and captured intracranial electrophysiological signals from the same targeted brain area. NeuroOne said it believes this combination has not previously been demonstrated in a convection-enhanced drug-delivery setting.

The approach could eventually help researchers study whether therapies can be delivered directly to seizure-related brain regions while monitoring local electrical activity. Potential benefits may include more precise treatment and reduced systemic exposure, but these possibilities remain unproven in people.

The results are preclinical and do not show that StereoCED reduces seizures, improves outcomes, or will receive regulatory approval.

Animal-Research Revenue and Human Studies Are the Next Catalysts

NeuroOne expects to recognize revenue from animal-use StereoCED devices during fiscal Q4 2026 after completing development earlier than expected. The company has not disclosed anticipated revenue, sales volume, or customer commitments.

Human investigational-use devices are expected to be released by the end of fiscal Q4 2026, with studies planned to begin later in the quarter. Those studies will be essential for evaluating the platform’s safety and technical performance in a clinical setting.

What the StereoCED Update Means for NMTC Investors

The successful procedures represent positive technical progress for NeuroOne’s investigational brain drug-delivery program. Investors should watch for the timing and scale of animal-device revenue, the launch of human studies, safety and feasibility data, regulatory developments, manufacturing readiness, and the company’s cash needs.

StereoCED could expand NeuroOne’s neurology-device portfolio if human studies are successful. For now, however, the platform remains an early-stage investigational technology with substantial clinical, regulatory, commercial, and financing risk.